NCT06322342: Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent |
|
|
| Recruiting | 2 | 24 | US | RVP-001, Mn-PyC3A | Reveal Pharmaceuticals Inc., National Cancer Institute (NCI) | Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Brain Cancer, Brain Tumor, Brain Neoplasm, Primary, Multiple Sclerosis, Multiple Sclerosis Brain Lesion, Neurofibroma, Acoustic Neuroma, CNS Tumor, CNS Lesion, CNS Metastases, CNS Cancer, CNS Lymphoma | 02/25 | 03/25 | | |
| Recruiting | 1 | 60 | RoW | Ablation Treatment, Arterial Angiography Only, Single Arm non-Randomized Ablation Treatment | Neurotronic, Inc., Libra Medical | Diabetes Mellitus, Type 2, Hypertension | 01/25 | 01/29 | | |
| Recruiting | 1 | 50 | RoW | Neurotronic Infusion Catheter | Neurotronic, Inc., Libra Medical | Diabetes Mellitus, Type 2, Hypertension | 01/25 | 01/29 | | |
NECTAR, NCT04232774: Neurotronic Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities |
|
|
| Completed | N/A | 22 | RoW | The Neurotronic arterial ablation catheter, NAA | Neurotronic, Inc., Libra Medical | Type 2 Diabetes Mellitus With Circulatory Complciation | 01/23 | 01/23 | | |
